Business Wire

VALANX Biotech and Fina Biosolutions Introduce ClickCRM for Rapid Conjugate Vaccine Development

KLOSTERNEUBURG, Austria & ROCKVILLE, Md.--(BUSINESS WIRE)--VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug and diagnostics ...
ascopubs.org

Novel protein drug conjugate ANXV-chemo and cytotoxic and anti-proliferative effects against human triple-negative breast cancer in vitro.

YB-800, a monoclonal antibody targeting the human neuronal pentraxin receptor (NPTXR), as a potential candidate for the design of a first in class antibody drug conjugate (ADC) as novel therapeutic ...
BioWorld

Protein-antibody conjugate shows significant antitumor activity in murine breast cancer model

Researchers from MD Anderson Cancer Center recently presented the discovery and preclinical evaluation of LLO-CD47, a novel protein-antibody conjugate linking anti-CD47 to Listeriolysin O (LLO), a ...
BioWorld

Elpiscience designs fusion protein consisting of NKG2A antibody conjugated to IL-2 mutant

Researchers from Elpiscience Biopharmaceuticals Inc. discussed the discovery and preclinical characterization of a novel NKG2A antibody-IL-2 mutant fusion protein – ES-015.129 – being developed as ...
ascopubs.org

Preclinical in vitro and in vivo evaluation of novel ANXV-chemo protein drug conjugate against human triple-negative breast cancer.

Treatment-related toxicities of antibody-drug conjugates in breast cancer: A Bayesian network meta-analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...